Renalytix (NASDAQ:RNLX) Trading Up 3.9%

Renalytix Plc (NASDAQ:RNLX) rose 3.9% on Friday . The stock traded as high as $0.30 and last traded at $0.30. 227,213 shares traded hands during trading, a decline of 86% from the average daily volume of 1,589,565 shares. The stock had previously closed at $0.29.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Renalytix in a report on Friday, July 12th.

Renalytix Stock Performance

The company has a market cap of $24.83 million, a PE ratio of -0.77 and a beta of 2.74. The company has a 50 day simple moving average of $0.33 and a two-hundred day simple moving average of $0.57.

Institutional Investors Weigh In On Renalytix

An institutional investor recently bought a new position in Renalytix stock. Levin Capital Strategies L.P. acquired a new stake in shares of Renalytix Plc (NASDAQ:RNLX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 555,000 shares of the company’s stock, valued at approximately $128,000. Levin Capital Strategies L.P. owned about 0.72% of Renalytix at the end of the most recent quarter. 9.92% of the stock is currently owned by institutional investors.

Renalytix Company Profile

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.